UPLOAD Filing
Enlivex Ltd.
Date: Dec. 29, 2025 · CIK: 0001596812 · Accession: 0000000000-25-011873
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292417
Letter
Re: Enlivex Therapeutics Ltd. Registration Statement on Form F-3 Filed December 23, 2025 File No. 333-292417 Dear Shachar Shlosberger:
December 29, 2025
Shachar Shlosberger Chief Financial Officer Enlivex Therapeutics Ltd. FISCHER (FBC & Co.) 146 Menachem Begin Street Tel Aviv 6492103, Israel
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Drew M. Altman
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> December 29, 2025 Shachar Shlosberger Chief Financial Officer Enlivex Therapeutics Ltd. FISCHER (FBC & Co.) 146 Menachem Begin Street Tel Aviv 6492103, Israel Re: Enlivex Therapeutics Ltd. Registration Statement on Form F-3 Filed December 23, 2025 File No. 333-292417 Dear Shachar Shlosberger: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Drew M. Altman </TEXT> </DOCUMENT>